NCR3 and neoplasm: Tumor cells can hamper NK immune response by inhibitory mechanisms such as indoleamine 2,3-dioxygenase (IDO) expression and/or PGE2 production in metastatic melanoma, modulating expression of NKp30, NKp44 and NKG2D [112].